|[July 29, 2014]
NIH Awards Imbed Bio a $1.5M Grant to Develop Advanced Wound Healing Nanofilm
MADISON, Wis. --(Business Wire)--
Imbed Biosciences, Inc, a medical device company developing advanced
materials for wound healing and surgical applications, announced today
that it has been awarded a $1.5M competitive Small Business Innovation
Research (SBIR) Phase II grant from National Institute for Arthritis and
Musculoskeletal and Skin Diseases (NIAMS), a division of National
Institutes of Health (NIH).
Ankit Agarwal, PhD, Founder/CEO of Imbed and the Principal Investigator
on the grant, said, "This award supports our ongoing investment to
develop unique polymeric nanofilm dressings containing silver
nanoparticles. The dressing would allow closure of hard-to-heal burns
and chronic wounds without infection or silver toxicity." In Phase I,
company validated the feasibility of employing these ultrathin conformal
wound dressings in contaminated wounds in mice, which expedited wound
closure by reducing bacterial colonization.
"It a very competitive award, which validates the uniqueness of this
polymeric nanofilm technology. A significant merit is that the concept
is adaptable to delivery of a wide range of bioactive molecules on
tissue surfaces, providing a broadly applicable healthcare materials
platform," said o-founder Nicholas Abbott, PhD, Professor in Department
of Chemical and Biological Engineering at University of
"This next-generation wound dressing will be applicable at the onset of
any wound treatment plan without silver toxicity. The nanofilm dressing
dissolves in wound over time, potentially reducing painful dressing
changes," said co-founder Prof. Michael Schurr, MD, burn and trauma
surgeon in School of Medicine at University of Colorado, Denver.
With this funding, Imbed plans to begin testing the nanofilm dressing in
pigs. "Clinical data from porcine wounds will be used to obtain
regulatory clearance for human clinical trials," said co-founder Prof.
Jonathan McAnulty, DVM, PhD, leading porcine studies as a part of this
grant in School of Veterinary Medicine at University of
"Wound healing research is an important component of the NIAMS
portfolio. It is part of an effort to reduce the impact of human skin
wounds on public health and the economy. This SBIR Phase II award to
Imbed Bio reflects our commitment to meet this public need," said Dr.
Hung Tseng, Program Director of the Skin Repair, Regeneration and
Pigmentation Program in the Division of Skin and Rheumatic Diseases at
"We have a team of renowned experts in surface engineering, microbiology
and surgical sciences committed to bring this wound healing nanofilm
technology into clinics," said Agarwal.
About Imbed Biosciences:
Imbed Biosciences Inc. is a privately held medical device company
located in Madison, WI. Company has patent-pending technologies on
polymeric nanofilms and microfilms for delivering tailored loadings
bioactive molecules on tissue surfaces. Company's vision is to develop
next-generation surgical devices that can reduce patient pain and
overall treatment costs, including antimicrobial dressings for dermal
wounds, hernia surgical meshes, barrier films for gastro-intestinal
defects, and dural membranes. For more information, visit http://www.imbedbio.com.
[ Back To Technology News's Homepage ]